A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate

Lisa A. Jackson, Richard Rupp, Athanasia Papadimitriou, Derek Wallace, Marsha Raanan, Kelley J. Moss

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: As part of the ongoing search for an effective dengue vaccine, Takeda performed a phase 1b study to investigate the safety and immunogenicity of an early low-dose tetravalent dengue vaccine candidate formulation (LD-TDV), based on an attenuated serotype 2 backbone, when administered intradermally with an injector device (PharmaJet®), or needle-syringe. Methods: The study was performed in two centers in the US, in healthy 18–45 year old subjects with no history of dengue vaccination or disease. One or two vaccine doses were given on Day 0, and another dose or placebo on Day 90. Neutralizing antibodies were measured up to Day 270; safety was assessed as laboratory measurements and solicited and unsolicited adverse events on diary cards. Results: Changes in World Health Organization prequalification guidance for new vaccines concerning storage conditions favored the use of lyophilized preparations, and led to the early cessation of enrolment, but not before 67 subjects were enrolled in four treatment groups. Sixty-five subjects completed the planned schedule. There were no safety signals or serious adverse events. All vaccination regimens elicited neutralizing antibodies. Titers of neutralizing antibodies against serotypes 1 and 2 were higher than those against serotypes 3 and 4. There were no consistent increases in responses with two doses given either concomitantly or 90 days apart. Conclusions: Simultaneous injection of two LD-TDV doses was shown to have the potential to improve seroconversion rates to serotypes 1 and 2, and to increase serotype 2 antibody titers. A primary dose of LD-TDV administered by PharmaJet was shown to induce more rapid seroconversion to serotypes 1, 2, and 3 compared with administration by needle-syringe (ClinicalTrials.gov: NCT01765426).

Original languageEnglish (US)
JournalVaccine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Dengue Vaccines
dengue
immune response
vaccines
Safety
serotypes
dosage
Neutralizing Antibodies
neutralizing antibodies
Syringes
Needles
syringes
Vaccination
seroconversion
Vaccines
Dengue
vaccination
injectors
Serogroup
Appointments and Schedules

Keywords

  • Dengue
  • Intradermal
  • Low-dose
  • Tetravalent
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. / Jackson, Lisa A.; Rupp, Richard; Papadimitriou, Athanasia; Wallace, Derek; Raanan, Marsha; Moss, Kelley J.

In: Vaccine, 01.01.2018.

Research output: Contribution to journalArticle

Jackson, Lisa A. ; Rupp, Richard ; Papadimitriou, Athanasia ; Wallace, Derek ; Raanan, Marsha ; Moss, Kelley J. / A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate. In: Vaccine. 2018.
@article{777ab0c2f5754d36958c0c0ff1474f1c,
title = "A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate",
abstract = "Background: As part of the ongoing search for an effective dengue vaccine, Takeda performed a phase 1b study to investigate the safety and immunogenicity of an early low-dose tetravalent dengue vaccine candidate formulation (LD-TDV), based on an attenuated serotype 2 backbone, when administered intradermally with an injector device (PharmaJet{\circledR}), or needle-syringe. Methods: The study was performed in two centers in the US, in healthy 18–45 year old subjects with no history of dengue vaccination or disease. One or two vaccine doses were given on Day 0, and another dose or placebo on Day 90. Neutralizing antibodies were measured up to Day 270; safety was assessed as laboratory measurements and solicited and unsolicited adverse events on diary cards. Results: Changes in World Health Organization prequalification guidance for new vaccines concerning storage conditions favored the use of lyophilized preparations, and led to the early cessation of enrolment, but not before 67 subjects were enrolled in four treatment groups. Sixty-five subjects completed the planned schedule. There were no safety signals or serious adverse events. All vaccination regimens elicited neutralizing antibodies. Titers of neutralizing antibodies against serotypes 1 and 2 were higher than those against serotypes 3 and 4. There were no consistent increases in responses with two doses given either concomitantly or 90 days apart. Conclusions: Simultaneous injection of two LD-TDV doses was shown to have the potential to improve seroconversion rates to serotypes 1 and 2, and to increase serotype 2 antibody titers. A primary dose of LD-TDV administered by PharmaJet was shown to induce more rapid seroconversion to serotypes 1, 2, and 3 compared with administration by needle-syringe (ClinicalTrials.gov: NCT01765426).",
keywords = "Dengue, Intradermal, Low-dose, Tetravalent, Vaccine",
author = "Jackson, {Lisa A.} and Richard Rupp and Athanasia Papadimitriou and Derek Wallace and Marsha Raanan and Moss, {Kelley J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2018.05.028",
language = "English (US)",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate

AU - Jackson, Lisa A.

AU - Rupp, Richard

AU - Papadimitriou, Athanasia

AU - Wallace, Derek

AU - Raanan, Marsha

AU - Moss, Kelley J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: As part of the ongoing search for an effective dengue vaccine, Takeda performed a phase 1b study to investigate the safety and immunogenicity of an early low-dose tetravalent dengue vaccine candidate formulation (LD-TDV), based on an attenuated serotype 2 backbone, when administered intradermally with an injector device (PharmaJet®), or needle-syringe. Methods: The study was performed in two centers in the US, in healthy 18–45 year old subjects with no history of dengue vaccination or disease. One or two vaccine doses were given on Day 0, and another dose or placebo on Day 90. Neutralizing antibodies were measured up to Day 270; safety was assessed as laboratory measurements and solicited and unsolicited adverse events on diary cards. Results: Changes in World Health Organization prequalification guidance for new vaccines concerning storage conditions favored the use of lyophilized preparations, and led to the early cessation of enrolment, but not before 67 subjects were enrolled in four treatment groups. Sixty-five subjects completed the planned schedule. There were no safety signals or serious adverse events. All vaccination regimens elicited neutralizing antibodies. Titers of neutralizing antibodies against serotypes 1 and 2 were higher than those against serotypes 3 and 4. There were no consistent increases in responses with two doses given either concomitantly or 90 days apart. Conclusions: Simultaneous injection of two LD-TDV doses was shown to have the potential to improve seroconversion rates to serotypes 1 and 2, and to increase serotype 2 antibody titers. A primary dose of LD-TDV administered by PharmaJet was shown to induce more rapid seroconversion to serotypes 1, 2, and 3 compared with administration by needle-syringe (ClinicalTrials.gov: NCT01765426).

AB - Background: As part of the ongoing search for an effective dengue vaccine, Takeda performed a phase 1b study to investigate the safety and immunogenicity of an early low-dose tetravalent dengue vaccine candidate formulation (LD-TDV), based on an attenuated serotype 2 backbone, when administered intradermally with an injector device (PharmaJet®), or needle-syringe. Methods: The study was performed in two centers in the US, in healthy 18–45 year old subjects with no history of dengue vaccination or disease. One or two vaccine doses were given on Day 0, and another dose or placebo on Day 90. Neutralizing antibodies were measured up to Day 270; safety was assessed as laboratory measurements and solicited and unsolicited adverse events on diary cards. Results: Changes in World Health Organization prequalification guidance for new vaccines concerning storage conditions favored the use of lyophilized preparations, and led to the early cessation of enrolment, but not before 67 subjects were enrolled in four treatment groups. Sixty-five subjects completed the planned schedule. There were no safety signals or serious adverse events. All vaccination regimens elicited neutralizing antibodies. Titers of neutralizing antibodies against serotypes 1 and 2 were higher than those against serotypes 3 and 4. There were no consistent increases in responses with two doses given either concomitantly or 90 days apart. Conclusions: Simultaneous injection of two LD-TDV doses was shown to have the potential to improve seroconversion rates to serotypes 1 and 2, and to increase serotype 2 antibody titers. A primary dose of LD-TDV administered by PharmaJet was shown to induce more rapid seroconversion to serotypes 1, 2, and 3 compared with administration by needle-syringe (ClinicalTrials.gov: NCT01765426).

KW - Dengue

KW - Intradermal

KW - Low-dose

KW - Tetravalent

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85047066283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047066283&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2018.05.028

DO - 10.1016/j.vaccine.2018.05.028

M3 - Article

JO - Vaccine

JF - Vaccine

SN - 0264-410X

ER -